Accueil Ernstrade Bourse Actualite Stock

plus500
Place de cotation: London Stock Exchange

Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect.  All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D currently has a pipeline of 13 preclinical programmes, covering disease areas such as rheumatoid arthritis, multiple sclerosis and cancer, and is currently conducting subject trials in Irritable Bowel Syndrome and Paediatric Crohn's Disease.  The programmes in Paediatric Ulcerative Colitis and Paediatric Crohn's Disease have both been granted Orphan Drug Status by the FDA.


 

http://www.4dpharmaplc.com/

Copyright  2017  Ernstrade